The impact of GLP-1 receptor agonists on major adverse cardiovascular events among hidradenitis suppurativa, psoriasis, and atopic dermatitis patients: A population-based cohort study
Need to claim your poster? Find the KiKo table at the conference and they'll help
you get set up.
Presented at: Society for Investigative Dermatology 2025
Date: 2025-05-07 00:00:00
Views: 2
Summary: The cardioprotective potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in hidradenitis suppurativa (HS), psoriasis (PsO), and atopic dermatitis (AD) remains understudied. Patients with these inflammatory skin diseases are at a higher risk of adverse cardiovascular events. Among HS, PsO, and AD patients, we aim to compare cardiovascular outcomes in patients who use GLP-1RAs versus those who do not. Using the TriNetX Research Network (2005-2024), we conducted a population-based cohort study. We identified patients aged ≥12 years with HS, PsO, or AD who were prescribed GLP-1RAs, along with propensity-matched controls with the same skin diseases who were not on GLP-1RAs. GLP-1RA users with HS (N=19,920), PsO (N=41,873), or AD (N=24,761) had a significantly reduced risk for cerebrovascular disease (CVD), ischemic heart disease (IHD), heart failure (HF), and atherosclerosis versus non-users (p<0.05). For HS, adjusted odds ratios (aOR) were: CVD, aOR=0.73 (95% CI, 0.66-0.80); IHD, aOR=0.77 (95% CI, 0.72-0.81); HF, aOR=0.71 (95% CI, 0.66-0.75); atherosclerosis, aOR=0.75 (95% CI, 0.68-0.81). For PsO, aORs were: CVD, aOR=0.74 (95% CI, 0.68-0.80); IHD, aOR=0.90 (95% CI, 0.86-0.95); HF, aOR=0.79 (95% CI, 0.74-0.83); atherosclerosis, aOR=0.77 (95% CI, 0.73-0.82). For AD, aORs were: CVD, aOR=0.74 (95% CI, 0.67-0.83); IHD, aOR=0.89 (95% CI, 0.83-0.95), HF, aOR=0.78 (95% CI, 0.72-0.84); atherosclerosis, aOR=0.78 (95% CI, 0.73-0.84). Our findings suggest that GLP-1RA use is associated with a significantly reduced risk of CVD, IHD, HF, and atherosclerosis in patients with HS, PsO, and AD. Given the increased cardiovascular risk in individuals with these inflammatory skin diseases, GLP-1RAs may offer a cardioprotective benefit beyond their established metabolic effects. Elaine J. Ma<sup>1</sup>, Alyssa Roberts<sup>1</sup>, Charlotte Jeong<sup>1</sup>, Peichi Chou<sup>1</sup>, Abigail Katz<sup>1</sup>, Yvonne Nong<sup>1</sup>, Matthew Yan<sup>1</sup>, Nicole A. Johnsen<sup>1</sup>, April Armstrong<sup>1</sup> 1. Division of Dermatology, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, United States. Clinical Research: Epidemiology and Observational Research